CTFG
HRTX icon

Capstone Triton Financial Group’s Heron Therapeutics HRTX Stock Holding History

Capstone Triton Financial Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$21K – 200
2020
Q4 		$21K Buy
+1,000
New +$17.4K 0.01% 278

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Capstone Triton Financial Group's HRTX Position: Q1 2021 in Review

Capstone Triton Financial Group sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 1,000 shares — an estimated $21K sold.

Capstone Triton Financial Group first reported a position in HRTX in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

  • Capstone Triton Financial Group reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Capstone Triton Financial Group sold 1,000 Heron Therapeutics shares in Q1 2021, an estimated $21K.
  • Capstone Triton Financial Group first reported a position in Heron Therapeutics in Q4 2020 and held it in 1 quarter.
  • Capstone Triton Financial Group's Heron Therapeutics position peaked at $21K in Q4 2020.
  • 193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Capstone Triton Financial Group's 13F filing for Q1 2021, filed 17 May 2021.